Clinical proof of concept was shown in two ongoing, multicentre, phase I clinical trials, in which 7 children and 14 adults with R/R B-ALL received allogeneic TALENs-edited CD19 CAR-T cells and 14 (67%) of 21 patients achieved CR/CRi 28 days after infusion. Here, CD19 is linked to acute lymphoblastic leukemia.